The American Diabetes Associations (ADA) will hold its 73rd Scientific Sessions on June 21-25, 2013, in Chicago, IL. The Scientific Session introduces new program features and advancements that will make the meeting one of the most interesting and interactive conferences on diabetes to date. More than 1,200 cutting-edge presentations by prestigious diabetes experts will explore the latest research breakthroughs.
NOW AVAILABLE: ADA 2013 Conference Coverage
Highlights from American Diabetes Associations (ADA) which took place on June 21-25, 2013, in Chicago, IL, are available in a newsletter published by The American Journal of Managed Care.
Diabetes Cost-Effectiveness Studies and How They Affect Real-World Treatment
Cost-effectiveness analyses (CEAs) have real effects on therapeutic approaches for patients with type 2 diabetes mellitus (T2DM). Dr. Gilmer discusses how studies like the United Kingdom Prospective Diabetes Study (UKPDS) and the Diabetes Prevention Program (DPP) have affected how researchers and scientists evaluate the benefits of new treatments.
Connecting the Dots: Global Epidemiology of Type 1 Diabetes and National Income Levels
Jaakko Tuomilehto, MD, PhD, a professor of public health at the University of Helsinki in Finland provides global epidemiological data for T1DM and discusses the World Health Organization's Diabetes Mondiale (DiaMond) study. He compares the rates of incidences of T1DM among well-developed, high-income countries to low- and middle-income nations and takes note of the epidemiological trends.
Novel SGLT-2 Inhibitors: The Impact on Outcomes in Diabetes and Cardiovascular Health
Bernard Zinman, MD, the director of the Leadership Sinai Centre for Diabetes and the Sam and Judy Pencer Family Chair in Diabetes Research at Mount Sinai Hospital and the University of Toronto in Canada, discusses the new therapies, SGLT-2 inhibitors, that are now approved in the United States and European Union. These drug therapies have shown clinical benefits in both type 1 and type 2 diabetes, and may also improve cardiovascular outcomes for patients with type 2 diabetes
Ronald J. Sigal, MD, MPH, Discusses the Reality of Exercise and Physical Activity Goals for Most Patients
Ronald J. Sigal, MD, MPH, a professor of medicine, cardiac sciences, kinesiology, and community health sciences at the University of Calgary in Canada, and a Health Senior Scholar at the Alberta Heritage Foundation for Medical Research, pulls from his experience to discuss the reality of the current expectations and goals for exercise and physical activity in the overweight or obese patient with diabetes, and offers his solutions.
Diabetes Coaching Services in the Pharmacy Setting
Carl Dean Benton, RPh, explains how pharmacists can contribute to improvements in patient care through counseling programs. With the provisions of the Affordable Care Act, many insurers may begin to recognize the benefits of pharmacist-driven counseling initiatives, and integrate these programs to help improve outcomes for patients with type 2 diabetes.
Pharmacotherapy for Obesity: Filling a Therapeutic Gap
In this session, Robert Eckel, MD, discussed new and emerging therapies for obesity. New agents fill a therapeutic gap by allowing patients to achieve weight loss between 5% and 15% of body weight, leading to improved outcomes in patients with type 2 diabetes and metabolic disease.
Todd Brusko, PhD, Remarks on Evolving Role of Immunoregulation in Type 1 Diabetes
Todd Brusko, PhD, of the Todd M. Brusko Laboratory at the University of Florida College of Medicine, discussed how knowledge of regulatory T-cells has grown and improved, and noted that research has now entered a phase of harnessing the potential of our immune system through specific cell populations to combat root causes of type 1 diabetes (T1DM).
Non-Glycemic Effects of Glucagon-Like Peptide-1 Agonists and Dipeptidyl Peptidase-4 Inhibitors
Glucagon-like peptide-1 (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are associated with additional effects beyond prolonging the effect of incretins. Laurie Baggio, PhD, reviewed many of the studies showing the independent anti-inflammatory effects of these drugs, which may be explored for future indications. These effects may help scientists understand some of the mechanisms behind inflammation in the body, as explained by Julio Ayala, PhD. Finally, concerns about pancreatitis with DPP-4 inhibitors and GLP-1 agonists may be largely unfounded, as explained by Vanita Aroda, MD.
Impact of Quality Care Measures on Patient Care
Rodney Hayward, MD, and Sheldon Greenfield, MD, discussed the benefits of quality care measures and explored some of the remaining areas for improvement. Some groups advocate for the use of composite quality care measures that reflect treatment guidelines and suggest that the same targets not be applied to all patients.